<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02329288</url>
  </required_header>
  <id_info>
    <org_study_id>SecondMMU2014</org_study_id>
    <nct_id>NCT02329288</nct_id>
  </id_info>
  <brief_title>Retrobulbar Triamcinolone Acetonide Injection in the Treatment of NA-AION</brief_title>
  <official_title>Retrobulbar Triamcinolone Acetonide Injection in the Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Military Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      NAION produces an ischemic insult in the optic nerve head presumably due to the hypoperfusion
      of the short ciliary arteries that supply it.

      Intravenous injection of glucocorticoid have proven to be effective in treatment of
      Nonarteritic Anterior Ischemic Optic Neuropathy,but have some side effects. the investigators
      believe that offering them Retrobulbar Triamcinolone Acetonide Injection that might halt the
      progression of the visual acuity and visual field loss if our hypothesis is correct, would
      greatly improve their chances of avoiding blindness.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of Best corrected visual acuity(BCVA)</measure>
    <time_frame>baseline and 1month, 3month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of Visual Field</measure>
    <time_frame>baseline and 1month, 3month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Triamcinolone Acetonide</condition>
  <condition>Optic Neuropathy, Ischemic</condition>
  <arm_group>
    <arm_group_label>Triamcinolone Acetonide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40mg/1ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide</intervention_name>
    <arm_group_label>Triamcinolone Acetonide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Sudden mono ocular vision loss associated with optic disc edema and positive Marcus Gunn
        (&lt;30 days)

        Exclusion Criteria:

        Any eye disease except NAION(Nonarteritic Anterior Ischemic Optic Neuropathy) Neurologic
        defect Abnormal ESR, CRP, any history of retina or vitreal surgery Severe corneal opacity
        which makes retina examination impossible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>shihong zhao</last_name>
    <role>Study Director</role>
    <affiliation>department of ophthalmology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>DONGYAN PAN, Dr</last_name>
    <phone>86-21-31161995</phone>
    <email>campus@126.com</email>
  </overall_contact>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2014</study_first_submitted>
  <study_first_submitted_qc>December 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2014</study_first_posted>
  <last_update_submitted>March 27, 2015</last_update_submitted>
  <last_update_submitted_qc>March 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Second Military Medical University</investigator_affiliation>
    <investigator_full_name>pandongyan</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Neuropathy, Ischemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

